“We can’t make any claims yet, but we’re pointing in all the right directions.” United Neuroscience has had a successful phase II trial and now working on the third phase of trials for the vaccine.
According to the Centers for Disease Control and Prevention (CDC), Alzheimer's Disease is one of the top causes of death for people aged 65 and above. It is also estimated that the disorder affects around 5.7 million Americans.
Although many people believe that dementia is a synonym for Alzheimer's, it's not the same. While dementia is a term collectively used for impaired memory thinking skills, Alzheimer's disease is a specific form of dementia. According to Alzheimers.net, Alzheimer's is responsible for 50-70% of all dementia cases.
And for many decades, the medical community have been trying to tackle Alzheimer's disease. Although many companies have worked towards finding a cure, more so vaccination for the disorder -- there has been very little success so far.
To add to the woes, some medications have also reportedly shown negative side-effects in patients. This is owing to the fact that researchers weren't able to reliably keep patients’ immune systems from kicking into overdrive when they got exposed to the vaccines.
However, it might all change now considering there is a company called United Neuroscience that claims it might have just found a vaccine for Alzheimer's and on the verge of reality sooner than you think.
“We are doing better than the placebo on all these things,” United Neuroscience CEO Mei Mei Hu was quoted as saying by Bloomberg. United Neuroscience is a four-year-old start-up company based out of Dublin.
“We can’t make any claims yet, but we’re pointing in all the right directions.” This comment comes after a successful phase II trial and now the company has already started working on the third phase of trials for its vaccine.
Genuine breakthrough?— Rick Spence (@rickspence) January 25, 2019
For 2 decades, biotech firms tackled Alzheimer’s disease with little success - until Dublin startup United Neuroscience. "In a small clinical trial, 96% of patients responded, without serious side effects, to its Alzheimer’s vaccine."https://t.co/aWAWh1Oshk pic.twitter.com/bgyA7zFtij
United Neuroscience Inc. does not claim that it can cure or prevent Alzheimer’s completely, however, there have been previously unreported results from a clinical trial that showed 96 percent of patients responded positively having no serious side-effects. The vaccine is called UB-311. According to the company report, the patients have even shown improved brain function and a reduction in the protein plaque gumming up their neurons.
“They have taken thoughtful initial steps with this very promising technology,” Eric Reiman, a leading Alzheimer’s researcher and adviser to United Neuroscience, told Bloomberg. “But this is still the beginning of the beginning.”
The vaccine was developed by Chang Yi Wang, a top scientist in the immunology and biochemistry field. According to Wired, Wang's research for UB-311 involved endobody vaccines, which is a new field in immunology. If you are not aware of endobody vaccines, it helps the body's immune system deal with malfunctioning internal parts of the body that it otherwise ignores. This is different from how most vaccines help prepare our body’s immune system to fight away diseases caused by bacteria or viruses entering our blood.
“We were able to generate some antibodies in all patients, which is unusual for vaccines,” Wang told Wired about the successful UB-311 trial. “We’re talking about almost a 100% response rate."